Tags : GRAVITAS-301

Incyte Reports Results of Itacitinib in GRAVITAS-301 P-III Study for

Vartika Singh January 3, 2020

Shots: The GRAVITAS-301 (NCT03139604) P-III study involves assessing of Itacitinib + corticosteroid vs PBO + corticosteroid for 1L patients with acute GVHD The P-III study did not meet its 1EP […]readmore

Tags : GRAVITAS-301

Incyte Reports Results of Itacitinib in GRAVITAS-301 P-III Study for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : GRAVITAS-301

Incyte Reports Results of Itacitinib in GRAVITAS-301 P-III Study for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company